What is the clinical evidence from this study?

Study design: Review. Population: Heart failure. Intervention: Guideline-directed medical therapy.

What does this research mean for the field?

Although the relative efficacy of guideline-directed heart failure medical therapy is preserved in older adults, patients aged ≥75 years are systematically underrepresented in pivotal trials and experience higher rates of adverse events, necessitating clinically adapted dosing and closer monitoring. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The review aims to evaluate the relevance and tolerability of heart failure pharmacotherapy in adults aged ≥75 years.

May 24, 2026Drugs & Aging

Guideline-Directed Heart Failure Pharmacotherapy in Adults Aged ≥75 Years: Evidence Gaps, Tolerability, and Implications for Clinical Practice

View Full Paper

Ask AI

Bookmark

Key result

Major HF trials highlight a persistent evidence gap for GDMT in adults aged ≥75 years.

Why the study?

Heart failure trials predominantly enroll younger, less frail populations, leaving adults aged ≥75 years underrepresented and questioning the generalizability of guideline-directed medical therapy to geriatric practice.

Does guideline-directed medical therapy improve outcomes and remain tolerable in adults aged ≥75 years with heart failure?

Population

Pivotal randomized controlled trials underpinning modern heart failure pharmacotherapy

Design

Structured narrative critical review

Authors

RERémi EsserHeart Failure & Transplant OMOlivier MaurouHeart Failure & Transplant MLMarine LarbaneixHeart Failure & Transplant

Discussion

Member takes

Implication

Underrepresentation of adults ≥75 years in HF trials warrants cautious GDMT extrapolation; leaves open net benefit and tolerability in this population.

Key Points

The review aims to evaluate the relevance and tolerability of heart failure pharmacotherapy in adults aged ≥75 years.
Conducted a structured narrative critical review of pivotal randomized controlled trials.
Extracted data on age distribution, exclusion criteria, efficacy, and safety outcomes without formal systematic selection.
Interpreted trial findings using established geriatric frameworks, focusing on frailty and multimorbidity.
Mean participant age in major trials was 61 to 67 years with limited inclusion of patients aged ≥75 years.
Older adults faced higher rates of hypotension, renal dysfunction, and treatment discontinuation, despite preserved relative treatment efficacy.
Key geriatric domains such as frailty, functional status, and cognition were rarely included in trial designs.

Structured PICO

Does guideline-directed medical therapy improve outcomes and remain tolerable in adults aged ≥75 years with heart failure?

Population

Adults aged ≥75 years with heart failure

Intervention

Guideline-directed medical therapy (GDMT)

Outcome

Applicability, tolerability, and clinical relevance of guideline-directed medical therapy

This review highlights the underrepresentation of adults aged ≥75 years in heart failure trials and recommends adapting guideline-directed medical therapy with slower titration and closer monitoring in this population.

Limitations

Key geriatric domains—frailty, functional status, cognition, nutrition, and polypharmacy—were systematically absent from trial designs.
Very limited inclusion of patients aged ≥75 years and very limited representation of patients aged ≥80 years.
No formal systematic selection or meta-analysis

Cite This Study

Esser et al. (2026) conducted a review in Heart failure. Guideline-directed medical therapy was evaluated. Major heart failure trials had mean participant ages ranging from 61 to 67 years, highlighting a persistent evidence gap for guideline-directed medical therapy in adults aged ≥75 years.

synapsesocial.com/papers/6a12994f48a0ea166567406d https://doi.org/10.1007/s40266-026-01302-z

Topics

HFrEF treatment Heart failure

View Full Paper

Ask AI

Bookmark

May 24, 2026Drugs & Aging

Guideline-Directed Heart Failure Pharmacotherapy in Adults Aged ≥75 Years: Evidence Gaps, Tolerability, and Implications for Clinical Practice

View Full Paper

Ask AI

Bookmark

Key result

Major HF trials highlight a persistent evidence gap for GDMT in adults aged ≥75 years.

Why the study?

Does guideline-directed medical therapy improve outcomes and remain tolerable in adults aged ≥75 years with heart failure?

Population

Pivotal randomized controlled trials underpinning modern heart failure pharmacotherapy

Design

Structured narrative critical review

Authors

RERémi EsserHeart Failure & Transplant OMOlivier MaurouHeart Failure & Transplant MLMarine LarbaneixHeart Failure & Transplant

Discussion

Member takes

Implication

Underrepresentation of adults ≥75 years in HF trials warrants cautious GDMT extrapolation; leaves open net benefit and tolerability in this population.

Key Points

The review aims to evaluate the relevance and tolerability of heart failure pharmacotherapy in adults aged ≥75 years.
Conducted a structured narrative critical review of pivotal randomized controlled trials.
Extracted data on age distribution, exclusion criteria, efficacy, and safety outcomes without formal systematic selection.
Interpreted trial findings using established geriatric frameworks, focusing on frailty and multimorbidity.
Mean participant age in major trials was 61 to 67 years with limited inclusion of patients aged ≥75 years.
Older adults faced higher rates of hypotension, renal dysfunction, and treatment discontinuation, despite preserved relative treatment efficacy.
Key geriatric domains such as frailty, functional status, and cognition were rarely included in trial designs.

Structured PICO

Does guideline-directed medical therapy improve outcomes and remain tolerable in adults aged ≥75 years with heart failure?

Population

Adults aged ≥75 years with heart failure

Intervention

Guideline-directed medical therapy (GDMT)

Outcome

Applicability, tolerability, and clinical relevance of guideline-directed medical therapy

Limitations

Key geriatric domains—frailty, functional status, cognition, nutrition, and polypharmacy—were systematically absent from trial designs.
Very limited inclusion of patients aged ≥75 years and very limited representation of patients aged ≥80 years.
No formal systematic selection or meta-analysis

Cite This Study

synapsesocial.com/papers/6a12994f48a0ea166567406d https://doi.org/10.1007/s40266-026-01302-z

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Topics

HFrEF treatment Heart failure

View Full Paper

Ask AI

Bookmark